93475-48-0Relevant academic research and scientific papers
3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES
-
Page/Page column 142-143, (2008/12/04)
The invention relates to 3-heterocyclyl indolyl compounds capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, said compounds having the formula (I) wherein R1, R2, R3, R4, RA, Y and Y are as defined in the specification. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the protection of cells.
4-Bromo-1-methoxy-N-[2-(4-aryl-1-piperazinyl)ethyl]-2- naphthalenecarboxamides: Selective dopamine D3 receptor partial agonists
Glase, Shelly A.,Akunne, Hyacinth C.,Heffner, Thomas G.,Johnson, Stephen J.,Kesten, Suzanne R.,Mackenzie, Robert G.,Manley, Peter J.,Pugsley, Thomas A.,Wright, Jon L.,Wise, Lawrence D.
, p. 1361 - 1366 (2007/10/03)
A series of 4-bromo-1-methoxy-N-[2-(4-aryl-1-piperazinyl)ethyl]-2- naphthalenecarboxamide dopamine (DA) D3 receptor agonists has been identified. These compounds were found to be selective for DA D3 over D2 receptors and were shown to be partial to full agonists as measured by stimulation of mitogenesis in D3-transfected CHO p-5 cells.
